Harmony Biosciences Holdings, Inc. HRMY Net debt / EBITDA

Net debt / EBITDA at other companies

Jazz PharmaceuticalsJAZZ

5.6×-2.2×

AlkermesALKS

5.9×+5.1×

Stoke Therapeutics, Inc.STOK

-2.8×—

Acadia PharmaceuticalsACAD

-3.2×-4.7×

Zevra Therapeutics, Inc.ZVRA

-1.6×—

AdaptHealthAHCO

4.7×+1.3×

FAQ

What is Harmony Biosciences Holdings, Inc.'s net debt / EBITDA?

Harmony Biosciences Holdings, Inc. (HRMY) reported net debt / EBITDA of -2× in Q1 2026.

How has Harmony Biosciences Holdings, Inc.'s net debt / EBITDA changed year-over-year?

Harmony Biosciences Holdings, Inc.'s net debt / EBITDA decreased by 39.9% year-over-year, from -1.4× to -2×.

What is the long-term trend for Harmony Biosciences Holdings, Inc.'s net debt / EBITDA?

Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s net debt / EBITDA has grown at a 13.7% compound annual growth rate (CAGR), from -1.3× to -2.5×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.